69P Relationship between BRCA genotype by location and duration of response to iPARP treatment: Real-life data

Treatment with PARP inhibitors in the maintenance of ovarian cancer has been a revolution natural history disease, especially those cases carrying BRCA mutations. Within this population, it described that alterations RING region BRCA-1 confer resistance to by forming hypomorphic protein can activate RAD51. There is little data on whether different functional domains 1 and 2 genes modulate response there no validation these real-life data. Among 195 collected high-grade cancer, 38 patients were identified as gene mutation carriers, either germinal or somatic. To determine domain each mutations, Clinvar search engine was used. Statistical analysis performed using nonparametric tests due small sample size. 27 treated iPARP are included study. The median age at diagnosis 55 years. 33% first line maintenance, 42% after relapse 25% subsequent lines. 15% received Niraparib, 78% Olaparib 7% combination Bevacizumab treatment. carriers (55.5% total), 13% had mutations DBD domain, BRCT 6% RING. rest located outside protein. BRCA-2 mutation, 16% 58% With follow-up 23 months (range 2-79), thirty-three percent have experienced disease progression It noteworthy among progression-free interval only months. Even so, statistically significant differences detected between genotype interval. Despite number paucity events, differential pattern duration treatment apparent. In few benefit very limited, although require series larger numbers patients.